journal article·2023-03

A tricarbonyl rhenium(I) complex decorated with boron dipyrromethene for endoplasmic reticulum-targeted photodynamic therapy

Wen-Wen Feng, Bin-Fa Liang, Bai-Hua Chen, Qi-Yan Liu, Zheng-Yin Pan, Ying-Ju Liu, Liang He

Dyes and Pigments· Volume 211
Publisher page

Abstract

No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.

Source: Not provided · Quality: missing

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Photodynamic Therapy Research Studies · Luminescence and Fluorescent Materials

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (72)

Show source-provided references
1. Photodynamic therapy in dermatology: state-of-the-art10.1111/j.1600-0781.2010.00507.x ↗
2. Photodynamic therapy for infections: clinical applications10.1002/lsm.21080 ↗
3. Photodynamic therapy for cancer10.1038/nrc1071 ↗
4. Photodynamic therapy of cancer: an update
5. Imaging and photodynamic therapy: mechanisms, monitoring, and optimization10.1021/cr900300p ↗
6. Photodynamic therapy - mechanisms, photosensitizers and combinations10.1016/j.biopha.2018.07.049 ↗
7. Photodynamic therapy mediated by nontoxic core-shell nanoparticles synergizes with immune checkpoint blockade to elicit antitumor immunity and antimetastatic effect on breast cancer10.1021/jacs.6b09538 ↗
8. Bioinspired hybrid protein oxygen nanocarrier amplified photodynamic therapy for eliciting anti-tumor immunity and abscopal effect10.1021/acsnano.8b04371 ↗
9. Photodynamic therapy and immunity: an update10.1111/php.13253 ↗
10. Aggregation-induced emission (AIE) dots: emerging theranostic nanolights10.1021/acs.accounts.8b00060 ↗
11. Photosensitizers for photodynamic therapy10.1002/adhm.201900132 ↗
12. An updated overview on the development of new photosensitizers for anticancer photodynamic therapy10.1016/j.apsb.2017.09.003 ↗
13. Boosting cancer therapy with organelle-targeted nanomaterials10.1021/acsami.9b01370 ↗
14. Organelle-targeted photosensitizers for precision photodynamic therapy10.1021/acsami.1c02019 ↗
15. A nuclear targeted dual-photosensitizer for drug-resistant cancer therapy with NIR activated multiple ROS10.1039/C6SC00737F ↗
16. Nucleus-targeted organoiridium-albumin conjugate for photodynamic cancer therapy10.1002/anie.201813002 ↗
17. Pd@Au bimetallic nanoplates decorated mesoporous MnO2 for synergistic nucleus-targeted NIR-II photothermal and hypoxia-relieved photodynamic therapy10.1002/adhm.201901528 ↗
18. Mitochondria-targeted smart AIEgens: imaging and therapeutics10.1016/j.ccr.2022.214818 ↗
19. Cyclometalated iridium(iii) complexes for mitochondria-targeted combined chemo-photodynamic therapy10.1039/D0DT00180E ↗
20. Cancer-cell-activated in situ synthesis of mitochondria-targeting AIE photosensitizer for precise photodynamic therapy10.1002/anie.202017350 ↗
21. Cyclometalated iridium(III) complexes as lysosome-targeted photodynamic anticancer and real-time tracking agents10.1039/C5SC01955A ↗
22. A lysosome-localized thionaphthalimide as a potential heavy-atom-free photosensitizer for selective photodynamic therapy10.1016/j.dyepig.2020.108265 ↗
23. Red-light-responsive Ru complex photosensitizer for lysosome localization photodynamic therapy10.1021/acsami.0c22551 ↗
24. Facile synthesis of AIEgens with wide color tunability for cellular imaging and therapy10.1039/C8SC05805A ↗
25. BODIPYs revealing lipid droplets as valuable targets for photodynamic theragnosis10.1039/C9CC09397D ↗
26. Lipophilic neutral iridium(III) complexes for phosphorescence imaging of lipid droplets and potential photodynamic therapy10.1016/j.dyepig.2022.110387 ↗
27. Endoplasmic reticulum-localized iridium(III) complexes as efficient photodynamic therapy agents via protein modifications10.1021/jacs.6b05302 ↗
28. Endoplasmic reticulum-localized two-photon-absorbing boron dipyrromethenes as advanced photosensitizers for photodynamic therapy10.1021/acs.jmedchem.7b01907 ↗
29. Enhancing the ROS generation ability of a rhodamine-decorated iridium(iii) complex by ligand regulation for endoplasmic reticulum-targeted photodynamic therapy10.1039/D0SC04751A ↗
30. The endoplasmic reticulum: structure, function and response to cellular signaling10.1007/s00018-015-2052-6 ↗
31. Integrated endoplasmic reticulum stress responses in cancer10.1158/0008-5472.CAN-07-1705 ↗
32. Enzymatic assemblies disrupt the membrane and target endoplasmic reticulum for selective cancer cell death10.1021/jacs.8b04641 ↗
33. Triplet photosensitizers: from molecular design to applications10.1039/c3cs35531d ↗
34. Engineering of relevant photodynamic processes through structural modifications of metallotetrapyrrolic photosensitizers10.1016/j.ccr.2016.06.007 ↗
35. Critical overview of the use of Ru(II) polypyridyl complexes as photosensitizers in one-photon and two-photon photodynamic therapy10.1021/acs.accounts.7b00180 ↗
36. Dual function luminescent transition metal complexes for cancer theranostics: the combination of diagnosis and therapy10.1016/j.ccr.2018.11.013 ↗
37. Transition metal complexes as photosensitisers in one- and two-photon photodynamic therapy10.1016/j.ccr.2018.03.020 ↗
38. New designs for phototherapeutic transition metal complexes10.1002/anie.201905171 ↗
39. Recent advances in ruthenium(II) and iridium(III) complexes containing nanosystems for cancer treatment and bioimaging10.1016/j.ccr.2021.214016 ↗
40. Luminescent and photofunctional transition metal complexes: from molecular design to diagnostic and therapeutic applications10.1021/jacs.2c03437 ↗
41. Transition metal complexes and photodynamic therapy from a tumor-centered approach: challenges, opportunities, and highlights from the development of TLD143310.1021/acs.chemrev.8b00211 ↗
42. Underestimated potential of organometallic rhenium complexes as anticancer agents10.1021/cb500528c ↗
43. Mitochondrial localization of highly fluorescent and photostable BODIPY-based ruthenium(II), rhodium(III), and iridium(III) metal complexes10.1021/acs.inorgchem.9b00898 ↗
44. BODIPY-Ruthenium(II) bis-terpyridine complexes for cellular imaging and type-I/-II photodynamic therapy10.1021/acs.inorgchem.1c01850 ↗
45. Lysosome targeting bis-terpyridine ruthenium(II) complexes: photophysical properties and in vitro photodynamic therapy10.1021/acsabm.0c00647 ↗
46. BODIPY-based probes for the fluorescence imaging of biomolecules in living cells10.1039/C5CS00030K ↗
47. Photosensitization and controlled photosensitization with BODIPY dyes10.1016/j.ccr.2017.09.029 ↗
48. Application of multifunctional BODIPY in photodynamic therapy10.1016/j.dyepig.2020.108937 ↗
49. BODIPY photosensitizers based on PET and heavy atom effect: a comparative study on the efficient formation of excited triplet state and singlet oxygen in BODIPY dimers and monomers10.1016/j.jphotochem.2017.07.019 ↗
50. Fine-tuning the electronic structure of heavy-atom-free BODIPY photosensitizers for fluorescence imaging and mitochondria-targeted photodynamic therapy10.1039/D0SC01171A ↗
51. Release of CO and production of O-1(2) from a Mn-BODIPY photoactivated CO releasing molecule with visible light10.1021/acs.organomet.1c00331 ↗
52. Rational design of a lysosome-targeting and near-infrared absorbing Ru(ii)-BODIPY conjugate for photodynamic therapy10.1039/D0CC06926D ↗
53. Ruthenium(II) conjugates of boron-dipyrromethene and biotin for targeted photodynamic therapy in red light10.1021/acs.inorgchem.9b03178 ↗
54. Novel ruthenium(II) and iridium(III) BODIPY dyes: insights into their application in photodynamic therapy in vitro10.1039/c9pp00201d ↗
55. Real-time tracking of ER turnover during ERLAD by a rhenium complex via lifetime imaging10.1093/nsr/nwab194 ↗
56. A boron dipyrromethene (BODIPY)-Based Cu-II-Bipyridine complex for highly selective NO detection10.1002/chem.201502191 ↗
57. Rhenium bipyridine complexes for the recognition of glucose10.1021/ic010202b ↗
58. Targeted reversal and phosphorescence lifetime imaging of cancer cell metabolism via a theranostic rhenium(I)-DCA conjugate10.1016/j.biomaterials.2018.05.040 ↗
59. Recoding the cancer epigenome by intervening in metabolism and iron homeostasis with mitochondria-targeted rhenium(I) complexes10.1002/anie.202008624 ↗
60. Impairment of the autophagy-related lysosomal degradation pathway by an anticancer rhenium(i) complex10.1039/C9DT00322C ↗
61. A mitochondria-targeted iridium(iii)-based photoacid generator induces dual-mode photodynamic damage within cancer cells10.1039/C9CC04871E ↗
62. A compilation of singlet oxygen yields from biologically relevant molecules10.1111/j.1751-1097.1999.tb08240.x ↗
63. Dinuclear phosphorescent rhenium(I) complexes as potential anticancer and photodynamic therapy agents10.1039/D0DT02424D ↗
64. Standards for photoluminescence quantum yield measurements in solution
65. Cyclometalated iridium-BODIPY ratiometric O2 sensors10.1039/C9SC00696F ↗
66. Oncologic photodynamic therapy: basic principles, current clinical status and future directions10.3390/cancers9020019 ↗
67. Cytotoxic BODIPY-appended half-sandwich iridium(III) complex forms protein adducts and induces ER stress10.1021/acs.jmedchem.1c01335 ↗
68. Evaluation of the probe 2',7'-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress10.1021/tx00026a012 ↗
69. Quenching of singlet molecular oxygen (1O2) by azide anion in solvent mixtures10.1562/0031-8655(2001)074<0760:QOSMOO>2.0.CO;2 ↗
70. β-Elemonic acid inhibits the growth of human Osteosarcoma through endoplasmic reticulum (ER) stress-mediated PERK/eIF2α/ATF4/CHOP activation and Wnt/β-catenin signal suppression10.1016/j.phymed.2020.153183 ↗
71. Endoplasmic reticulum-mitochondria contacts: function of the junction10.1038/nrm3440 ↗
72. Apoptosis: controlled demolition at the cellular level10.1038/nrm2312 ↗